Squarepoint’s Belite Bio BLTE Stock Holding History

Squarepoint’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.71M	Buy	+16,981	New	+$2.86M	﹤0.01%	1964

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's BLTE Position: Q1 2026 in Review

Squarepoint opened a new position in Belite Bio (BLTE) in Q1 2026: 16,981 shares worth $2.71M. The stake represents ﹤0.01% of the portfolio and ranks #1964 among its holdings.

75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

Squarepoint held 16,981 shares of Belite Bio worth $2.71M as of Q1 2026.
Belite Bio was a new Squarepoint position in Q1 2026.
Belite Bio made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1964 holding.
75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.